phentolamine has been researched along with Multiple System Atrophy in 1 studies
Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.
phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.
Multiple System Atrophy: A syndrome complex composed of three conditions which represent clinical variants of the same disease process: STRIATONIGRAL DEGENERATION; SHY-DRAGER SYNDROME; and the sporadic form of OLIVOPONTOCEREBELLAR ATROPHIES. Clinical features include autonomic, cerebellar, and basal ganglia dysfunction. Pathologic examination reveals atrophy of the basal ganglia, cerebellum, pons, and medulla, with prominent loss of autonomic neurons in the brain stem and spinal cord. (From Adams et al., Principles of Neurology, 6th ed, p1076; Baillieres Clin Neurol 1997 Apr;6(1):187-204; Med Clin North Am 1999 Mar;83(2):381-92)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with multiple system atrophy (MSA) or pure autonomic failure (PAF), we studied the effect of oral yohimbine on seated systolic blood pressure (SBP), the effect of ganglionic blockade (with trimethaphan) on supine SBP and plasma catecholamine levels, and the effect of alpha(1)-adrenoreceptor blockade (phentolamine) on supine SBP." | 5.09 | Sympathetically mediated hypertension in autonomic failure. ( Biaggioni, I; Black, BK; Diedrich, A; Jordan, J; Pohar, B; Robertson, D; Shannon, JR, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shannon, JR | 1 |
| Jordan, J | 1 |
| Diedrich, A | 1 |
| Pohar, B | 1 |
| Black, BK | 1 |
| Robertson, D | 1 |
| Biaggioni, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure[NCT00223717] | Phase 1 | 152 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| Identifying the Pathophysiology of Neurogenic Orthostatic Hypotension and the Effects of Melatonin on Reducing Supine Hypertension in Peripherally Intact Versus Denervated Post-ganglionic Sympathetic Nerves[NCT02963181] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-03-01 | Terminated (stopped due to PI leaving) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for phentolamine and Multiple System Atrophy
| Article | Year |
|---|---|
Sympathetically mediated hypertension in autonomic failure.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Autonomic Nervous System Diseases; Bloo | 2000 |
Sympathetically mediated hypertension in autonomic failure.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Autonomic Nervous System Diseases; Bloo | 2000 |
Sympathetically mediated hypertension in autonomic failure.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Autonomic Nervous System Diseases; Bloo | 2000 |
Sympathetically mediated hypertension in autonomic failure.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Autonomic Nervous System Diseases; Bloo | 2000 |